SPHEROTM AccuCount Particles

Figure 56 Histograms of Cat. No. ACFP-100-3
(AccuCount Fluorescent Particles, 106 /mL, 10.2 µm, 3 mL) on a Stratedigm S1400.

• Contains particles with a known number of particles per mL
• Easy to use and cost-effective
• Available in several sizes to accommodate the target cell size to be counted
• Provided as blank, fluorescent, Rainbow, or Ultra Rainbow particles that can be used in multiple fluorescent channels of flow cytometers.

 

The SPHEROTM AccuCount Particles are designed to be used as reference particles with known number of particles per mL for counting the absolute cell number by flow cytometry. The SPHEROTM AccuCount Particles are very easy to use and are cost effective. The AccuCount Fluorescent Particles are fluorescent in FITC, PE and PE-Cy5 channel. Both AccuCount Fluorescent and AccuCount Blank (nonfluorescent) Particles are available in various particle sizes to accommodate the size of the cells to be counted. In addition, Spherotech also manufactures the AccuCount Rainbow Fluorescent Particles and AccuCount Ultra Rainbow Fluorescent Particles for detection in more fluorescent channels.

 

sphero accucount blank particles

sphero accucount blank particles

Specifications

Brand – Sphero

Classification – Education

Name – Sphero BOLT 15 Pack

Technology -Bluetooth

Country of Origin – CN

Overview

Immuno-oncology (IO) focuses on exploiting the immune system to elicit appropriate anti-tumor responses and to block the progression of cancer. The immune system is naturally equipped with defense mechanisms to prevent invasion by pathogens. Immunological checkpoints, such as programmed cell death protein-1 (PD-1) and CTLA-4, are an integral part of the repertoire of checks and balances available in the body for preventing attacks on its own immune cells. Such an ability to discriminate between self and non-self is critical for preventing uncontrolled immune responses.

Cancer cells and the tumor microenvironment, however, can adopt these immunological checkpoints to pose as “self” molecules and evade the natural defense of the body’s own immune system. Tumor cells can express the PD-1 ligand (PD-L1) on their surface to bind with PD-1 and activate this brake or off-switch of the immune system.

Immuno-oncology approaches involve breaking this manipulation of immune checkpoint proteins by using inhibitors (e.g., anti-PD-1/PD-L1 agents) to block PD-1/PD-L1 interaction and allow the recognition of tumor cells by the immune system.1 Combining immunotherapy with other standard of care options, such as surgery, radiotherapy, and chemotherapy, has also been adopted recently.

 

[Linking template=”default” type=”products” search=”sphero accucount blank particles” header=”3″ limit=”25″ start=”3″ showCatalogNumber=”true” showSize=”true” showSupplier=”true” showPrice=”true” showDescription=”true” showAdditionalInformation=”true” showImage=”true” showSchemaMarkup=”true” imageWidth=”” imageHeight=””]

Categories: BlogProduct